Is survodutide available yet?

No, survodutide is not on the market. Phase 2 trials were published in May 2024 with promising results in patients with obesity and MASH, a severe form of fatty liver. Based on these results, survodutide is currently in Phase 3 trials in people with obesity and overweight with and without type 2 diabetes. It also launched two global Phase 3 trials to further assess survodutide’s safety and efficacy in MASH.

German drugmaker Boehringer Ingelheim is hoping that survodutide can be launched in 2027 or 2028, but this is dependent on how well the drug performs in these new trials.